Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Infect Control Hosp Epidemiol ; 30(8): 769-77, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19563265

ABSTRACT

Prions cause various transmissible spongiform encephalopathies. They are highly resistant to the chemical and physical decontamination and sterilization procedures routinely used in healthcare facilities. The decontamination procedures recommended for the inactivation of prions are often incompatible with the materials used in medical devices. In this study, we evaluated the use of low-temperature hydrogen peroxide gas plasma sterilization systems and other instrument-processing procedures for inactivating human and animal prions. We provide new data concerning the efficacy of hydrogen peroxide against prions from in vitro or in vivo tests, focusing on the following: the efficiency of hydrogen peroxide sterilization and possible interactions with enzymatic or alkaline detergents, differences in the efficiency of this treatment against different prion strains, and the influence of contaminating lipids. We found that gaseous hydrogen peroxide decreased the infectivity of prions and/or the level of the protease-resistant form of the prion protein on different surface materials. However, the efficiency of this treatment depended strongly on the concentration of hydrogen peroxide and the delivery system used in medical devices, because these effects were more pronounced for the new generation of Sterrad technology. The Sterrad NX sterilizer is 100% efficient (0% transmission and no protease-resistant form of the prion protein signal detected on the surface of the material for the mouse-adapted bovine spongiform encephalopathy 6PB1 strain and a variant Creutzfeldt-Jakob disease strain). Thus, gaseous or vaporized hydrogen peroxide efficiently inactivates prions on the surfaces of medical devices.


Subject(s)
Anti-Infective Agents, Local/pharmacology , Decontamination/methods , Hydrogen Peroxide/pharmacology , Prions/drug effects , Sterilization/methods , Animals , Biological Assay , Cricetinae , Detergents/pharmacology , Drug Interactions , Equipment Contamination/prevention & control , Female , Gases/pharmacology , Humans , Mesocricetus , Prion Diseases/prevention & control , Prion Diseases/transmission , Stainless Steel , Treatment Outcome
2.
J Hosp Infect ; 72(4): 342-50, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19541387

ABSTRACT

With the detection of prions in specific tissues in variant and sporadic Creutzfeldt-Jakob diseases, efficient decontamination for human transmissible spongiform encephalopathy (TSE) agents, that is compatible with medical equipment, has become a major issue. We previously described the cleavage of prions on exposure to copper (Cu) and hydrogen peroxide (H(2)O(2)) and have used this property to develop efficient prion decontamination processes. To validate this approach, in-vitro assays on genuine human and animal prions using both brain homogenates and steel wires to mimic contamination of medical equipment were conducted. In-vivo experiments using steel wire in the hamster 263 K model were then used to evaluate the effect on prion infectivity. Assays on classical pathogens following international norms completed these prion experiments. In-vitro data confirmed the full decontamination efficacy of H(2)O(2)/Cu on different TSE strains. Combination of Cu with peracetic acid, used for endoscope disinfection, also revealed improved prion decontamination. Animal assay demonstrated efficacy on TSE infectivity of H(2)O(2)/Cu alone or in combination with detergents (reduction factor > or =5.25 log(10)). Assays on classical pathogens confirmed the disinfection properties of the different processes. Taken together, these new disinfection processes are efficient for both conventional and prion infectious agents and are, compatible with thermosensitive medical equipment. They can be adapted to hospitals' and practitioners' routine use, and they present reduced risks for the environment and for healthcare professionals.


Subject(s)
Cross Infection/prevention & control , Disinfection/methods , Equipment and Supplies, Hospital , Prion Diseases/prevention & control , Prions/drug effects , Animals , Bacteria/drug effects , Copper/pharmacology , Cricetinae , Disinfectants/pharmacology , Fungi/drug effects , Humans , Hydrogen Peroxide/pharmacology , Mesocricetus , Mice , Viruses/drug effects
3.
Pathol Biol (Paris) ; 56(7-8): 492-503, 2008.
Article in French | MEDLINE | ID: mdl-18842358

ABSTRACT

Tau interferon (IFN-tau) was shown to inhibit human immunodeficiency virus (HIV) replication in vitro more strongly than human IFN-alpha, particularly in human macrophages. IFN-tau efficiently inhibited the early steps of HIV biological cycle, decreasing intracellular HIV RNA and inhibiting the initiation of the reverse transcription of viral RNA into proviral DNA. In this study, the in vitro immunomodulatory effects of IFN-tau were explored in human macrophages. We found that IFN-tau increased the synthesis of the cellular antiviral factors, such as 2',5'-oligoadenylate synthetase/RNase L and MxA protein. These results suggested that IFN-tau induces the same antiviral pathways in macrophages as other type I IFNs. We found that IFN-tau increased the production of interleukins (IL)-10 and IL-6, but not of IL-1ss or TNF-alpha, in not infected and in in vitro HIV-1/Ba-L-infected macrophages. We also found that the neutralization of IL-6 biological activity in the cell culture supernatants of IFN-tau-treated macrophages led to a decrease in the antiretroviral effects of IFN-tau towards HIV RNA. In conclusion, anti-HIV effects of IFN-tau are mediated by several modes of action, mediated either directly by IFN-tau or via other cytokines, such as IL-6, also known to be induced by IFN-alpha.


Subject(s)
HIV-1/physiology , Interferon Type I/pharmacology , Interleukin-6/physiology , Macrophages/drug effects , Pregnancy Proteins/pharmacology , Virus Replication/drug effects , Antibodies, Monoclonal/pharmacology , Cell Differentiation , Cells, Cultured/drug effects , Cells, Cultured/virology , Cytokines/metabolism , Endoribonucleases/biosynthesis , Endoribonucleases/genetics , GTP-Binding Proteins/biosynthesis , GTP-Binding Proteins/genetics , Gene Expression Regulation/drug effects , HIV Reverse Transcriptase/metabolism , Humans , Interferon-alpha/physiology , Interleukin-10/biosynthesis , Interleukin-10/genetics , Interleukin-10/pharmacology , Interleukin-6/antagonists & inhibitors , Interleukin-6/biosynthesis , Interleukin-6/genetics , Lipopolysaccharides/pharmacology , Macrophages/metabolism , Macrophages/virology , Monocytes/cytology , Monocytes/drug effects , Myxovirus Resistance Proteins , Receptors, HIV/physiology , Recombinant Fusion Proteins/pharmacology
4.
Br J Pharmacol ; 154(1): 174-82, 2008 May.
Article in English | MEDLINE | ID: mdl-18332855

ABSTRACT

BACKGROUND AND PURPOSE: 5-HT (serotonin) is known to be involved in neuroinflammation and immunoregulation. The human immunodeficiency virus (HIV) targets cells such as monocytes/macrophages, which colocalize with 5-HT-releasing cell types, mostly platelets. In this study, we investigated the effects of 5-HT on HIV-1-infected macrophages in vitro. EXPERIMENTAL APPROACH: Human macrophages cultured in serum-free medium were treated over 7 days with 5-HT at three concentrations (0.01, 1 and 100 microM) with or without agonists and antagonists of 5-HT(1A) and 5-HT(2) receptors. After 7 days of treatment, macrophages were infected with HIV-1/Ba-L and virus replication was monitored over 16 days and expression of proviral HIV DNA was investigated by PCR after 24 h of infection. Cell surface expression of HIV-1/Ba-L receptor (CD4) and coreceptor (CCR5) was investigated by flow cytometry. The CCR5 ligand, macrophage inflammatory protein-1alpha (MIP-1alpha), was quantified by ELISA in cell culture supernatants and MIP-1alpha mRNA expression was assessed by reverse transcriptase-PCR. KEY RESULTS: In vitro, 5-HT downregulated the membranous expression of CCR5 and led to a decrease of HIV-1 infection, probably through its action on 5-HT(1A) receptors. 5-HT (100 microM) was also able to induce overexpression of MIP-1alpha mRNA leading to an increase of MIP-1alpha secretion by human macrophages. CONCLUSIONS AND IMPLICATIONS: The effects of 5-HT on HIV infection could be a consequence of the increase in MIP-1alpha concentrations and/or CCR5 receptor downregulation. These results suggest that 5-HT can inhibit the replication of HIV-1 in primary culture of human macrophages through its action on 5-HT(1A) receptors.


Subject(s)
HIV-1/drug effects , Macrophages/virology , Receptor, Serotonin, 5-HT1A/drug effects , Serotonin/pharmacology , 8-Hydroxy-2-(di-n-propylamino)tetralin/pharmacology , CD4 Antigens/biosynthesis , Cells, Cultured , DNA, Viral/biosynthesis , Humans , Piperazines/pharmacology , Pyridines/pharmacology , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Receptors, CCR5/metabolism , Serotonin 5-HT1 Receptor Agonists , Serotonin 5-HT1 Receptor Antagonists , Serotonin Antagonists/pharmacology , Serotonin Receptor Agonists/pharmacology , Virus Replication/drug effects , p38 Mitogen-Activated Protein Kinases/metabolism
5.
Pathol Biol (Paris) ; 55(10): 495-503, 2007 Dec.
Article in French | MEDLINE | ID: mdl-17913389

ABSTRACT

The neurotransmitter 5-hydroxytryptamine (5-HT), commonly known as serotonin, is released at peripheral sites from activated platelets. At inflammatory sites, macrophages and lymphocytes could be exposed to 5-HT concentrations up to 100 microM. Moreover, 5-HT could modulate cytokine secretion by monocytes/macrophages and immune functions through the uptake of 5-HT at these inflammatory sites from T cells and dendritic cells. HIV infection is also under the control of inflammatory processes (including T cell proliferation and cytokines secretion). On this basis, we studied explored herein the effects of 5-HT on HIV-1/Ba-L (macrophage-tropic virus) replication in primary cultures of human macrophages. This pharmacological study with isotype-selective receptor agonists and antagonist allowed us to show that the 100 microM 5-HT concentration via 5-HT(1A) subtype receptors could decrease HIV replication. This observation was associated with an increase of MIP-1alpha secretion such as an increase of MIP-1alpha mRNA production and with a decrease of HIV-coreceptor CCR5 cell surface expression. Our results point out for the first time the inhibitory effects of 5-HT on HIV replication in primary culture of human macrophages via activation of 5-HT(1A) subtype receptors.


Subject(s)
HIV/physiology , Macrophages/virology , Receptor, Serotonin, 5-HT1A/physiology , Serotonin/pharmacology , Virus Replication/drug effects , Antiviral Agents/therapeutic use , HIV/drug effects , Humans , Monocytes/virology , Virus Diseases/diagnosis , Virus Diseases/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...